Business strategy
The CGC's business strategy is based on optimal utilization, expansion and integration of fundamental and applied research activities of the participants. We believe that in this way we can contribute to the development of improved diagnostic methods as well as better treatment methods and products for cancer patients.
The CGC Proof of Concept Fund aims to support the transformation of a commercially interesting invention to a high-potential business case ready for transfer to a commercial third party. Funds from the scheme will be awarded to projects that are characterized by commercial rather than scientific potential. They are granted primarily for technical development or demonstration of proof of concept for a particular technology or invention.
The fund is open to not-for-profit research organizations in the whole of the Netherlands. Basic eligibility of proposals shall be subject to the following criteria:
- the application must relate to the field of cancer genomics
- the proposed project should significantly improve the chances of successful commercialization of an existing business case.
Other conditions:
- the maximum grant amount is €75k; funds must be fully matched by the receiving institution. Projects may not last longer than two years
- the receiving institution’s technology transfer office (TTO) must be involved at both the application and the project execution stage. Where such a function does not exist, applications can be filed in consultation with the valorization manager of the CGC: k.verhoef-at-nki.nl
- the NGI general grant conditions (Subsidievoorwaarden NGI Tweede fase version 3/12/07) apply.